• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

应用 SHSMA 封堵器经导管闭合膜周部和嵴内型室间隔缺损。

Transcatheter closure of perimembranous and intracristal ventricular septal defects with the SHSMA occluder.

机构信息

Department of Cardiology, Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, Fudan University, Shanghai, China.

出版信息

Catheter Cardiovasc Interv. 2012 Mar 1;79(4):666-74. doi: 10.1002/ccd.23344. Epub 2011 Dec 8.

DOI:10.1002/ccd.23344
PMID:22109986
Abstract

OBJECTIVES

The objective of this study was to evaluate the safety and efficacy of transcatheter closure of perimembranous ventricular septal defect (pmVSD) and intracristal VSD (icVSD) using the Shanghai Shape Memory Alloy (SHSMA) pmVSD occluder.

BACKGROUND

There is still limited experience with transcatheter closure of pmVSD and icVSD.

METHODS

Between January 2003 and September 2010, 348 patients with pmVSD and 47 patients with icVSD underwent transcatheter closure using a SHSMA pmVSD occluder.

RESULTS

The total successful closure rate in pmVSD and icVSD subjects was 97.4 and 78.7%, respectively. During the perioperative period, no death, major bleeding or hemolysis occurred in both groups. In pmVSD group, one case of occluder dislodgement, one case of pericardial tamponade, and two cases of thromboembolism occurred. None in icVSD group had these complications. During a median of 3.2 years of follow-up, there was no evidence of significant residual shunt and device-related valve regurgitation. None in icVSD group and 10 patients (2.9%) in pmVSD group had a persistent arrhythmia. Overall, only one patient (0.3%) with pmVSD acquired complete atrioventricular block requiring implantation of a permanent pacemaker. The rim from the tricuspid valve to the defect < 4 mm was the only predictor of arrhythmic complications after procedure (OR = 4.24; P = 0.021).

CONCLUSIONS

Transcatheter closure of pmVSD in selected patients using the SHSMA occluder is effective and safe. Transcatheter closure of icVSD in experienced hands using this device is also feasible and safe.

摘要

目的

本研究旨在评估使用上海形状记忆合金(SHSMA)膜周部室间隔缺损(pmVSD)封堵器经导管闭合膜周部室间隔缺损(pmVSD)和嵴内型室间隔缺损(icVSD)的安全性和有效性。

背景

经导管闭合 pmVSD 和 icVSD 的经验仍然有限。

方法

2003 年 1 月至 2010 年 9 月,348 例 pmVSD 患者和 47 例 icVSD 患者接受了 SHSMA pmVSD 封堵器经导管闭合治疗。

结果

pmVSD 和 icVSD 患者的总闭合成功率分别为 97.4%和 78.7%。在围手术期,两组均未发生死亡、大出血或溶血。pmVSD 组中,1 例封堵器移位,1 例心包填塞,2 例血栓栓塞。icVSD 组均无这些并发症。在中位随访 3.2 年期间,均无明显残余分流和器械相关瓣膜反流的证据。icVSD 组和 pmVSD 组各有 10 例(2.9%)患者持续存在心律失常。pmVSD 组中有 1 例(0.3%)患者出现完全性房室传导阻滞,需要植入永久性起搏器。三尖瓣瓣环至缺损<4mm 是术后发生心律失常并发症的唯一预测因素(OR=4.24;P=0.021)。

结论

在选择的患者中使用 SHSMA 封堵器经导管闭合 pmVSD 是有效和安全的。在有经验的医生手中,使用该器械经导管闭合 icVSD 也是可行和安全的。

相似文献

1
Transcatheter closure of perimembranous and intracristal ventricular septal defects with the SHSMA occluder.应用 SHSMA 封堵器经导管闭合膜周部和嵴内型室间隔缺损。
Catheter Cardiovasc Interv. 2012 Mar 1;79(4):666-74. doi: 10.1002/ccd.23344. Epub 2011 Dec 8.
2
Transcatheter Closure of Perimembranous and Intracristal Ventricular Septal Defects Using Amplatzer Duct Occluder II in Children.经导管应用 Amplatzer Ⅱ型封堵器闭合膜周部和嵴内型室间隔缺损。
J Interv Cardiol. 2021 Sep 11;2021:4091888. doi: 10.1155/2021/4091888. eCollection 2021.
3
Transcatheter Device Closure of Perimembranous and Intracristal Ventricular Septal Defects in Children: Medium- and Long-Term Results.经导管膜周部和嵴内型室间隔缺损封堵术治疗儿童室间隔缺损:中远期结果。
J Am Heart Assoc. 2021 Jun;10(11):e020417. doi: 10.1161/JAHA.120.020417. Epub 2021 May 17.
4
Transcatheter closure of perimembranous ventricular septal defect using Amplatzer ductal occluder.应用 Amplatzer 导管封堵器经导管闭合膜周部室间隔缺损。
Catheter Cardiovasc Interv. 2013 Dec 1;82(7):1141-6. doi: 10.1002/ccd.24810. Epub 2013 Aug 20.
5
Risk factors and outcomes of post-procedure heart blocks after transcatheter device closure of perimembranous ventricular septal defect.经导管膜周部室间隔缺损封堵术后发生心脏阻滞的危险因素和结局。
JACC Cardiovasc Interv. 2012 Apr;5(4):422-7. doi: 10.1016/j.jcin.2012.01.015.
6
Transcatheter closure of a perimembranous ventricular septal defect with Nit-Occlud Lê VSD Coil: A French multicentre study.经导管闭合膜周部室间隔缺损的 Nit-Occlud Lê VSD 线圈:一项法国多中心研究。
Arch Cardiovasc Dis. 2020 Feb;113(2):104-112. doi: 10.1016/j.acvd.2019.11.004. Epub 2020 Jan 22.
7
Transcatheter closure of perimembranous ventricular septal defects (VSD) with VSD occluder: early and mid-term results.经导管使用室间隔缺损封堵器闭合膜周部室间隔缺损:早期和中期结果
Heart Vessels. 2012 Jul;27(4):398-404. doi: 10.1007/s00380-011-0153-1. Epub 2011 May 27.
8
Arrhythmias after transcatheter closure of perimembranous ventricular septal defects with a modified double-disk occluder: early and long-term results.采用改良双盘封堵器经导管闭合膜周部室间隔缺损后的心律失常:早期及长期结果
Heart Vessels. 2012 Jul;27(4):405-10. doi: 10.1007/s00380-011-0155-z. Epub 2011 Jun 4.
9
Postimplant complications with transcatheter closure of congenital perimembranous ventricular septal defects: a single-center, longitudinal study from 2002 to 2011.经导管封堵先天性膜周部室间隔缺损植入后并发症:2002 年至 2011 年单中心纵向研究。
Catheter Cardiovasc Interv. 2013 Mar;81(4):666-73. doi: 10.1002/ccd.24638. Epub 2013 Feb 14.
10
Closure of perimembranous ventricular septal defects with aneurysmal tissue using the Amplazter Duct Occluder I: lessons learned and medium term follow up.应用 Amplazter 导管封堵器 I 闭合膜周部室间隔缺损合并瘤样组织:经验教训和中期随访。
Catheter Cardiovasc Interv. 2012 Nov 15;80(6):895-903. doi: 10.1002/ccd.23074. Epub 2012 Aug 20.

引用本文的文献

1
Optimized retrograde approach and device selection with Konar-MF™ for pediatric transcatheter ventricular septal defect closure.采用Konar-MF™进行小儿经导管室间隔缺损封堵时的优化逆行入路及器械选择
Turk Gogus Kalp Damar Cerrahisi Derg. 2025 Jul 21;33(3):301-311. doi: 10.5606/tgkdc.dergisi.2025.27178. eCollection 2025 Jul.
2
Short-term outcomes of transcatheter perimembranous ventricular septal defect closure using the konar-multifunctional occluder: the Taiwanese experience.使用科纳尔多功能封堵器经导管闭合膜周部室间隔缺损的短期结果:台湾地区经验
Front Cardiovasc Med. 2025 May 27;12:1572812. doi: 10.3389/fcvm.2025.1572812. eCollection 2025.
3
An observational study of symmetrical VSD occluder for transcatheter closure of ruptured sinus of Valsalva aneurysm.
一项关于对称型室间隔缺损封堵器经导管封堵瓦氏窦瘤破裂的观察性研究。
Exp Ther Med. 2024 Apr 4;27(6):244. doi: 10.3892/etm.2024.12532. eCollection 2024 Jun.
4
Progression of aortic regurgitation following transcatheter closure of intracristal ventricular septal defects in children: a mid- to long-term follow-up study.儿童经导管封堵嵴内型室间隔缺损后主动脉瓣反流的进展:一项中长期随访研究。
Front Cardiovasc Med. 2023 May 3;10:1190013. doi: 10.3389/fcvm.2023.1190013. eCollection 2023.
5
Percutaneous Transcatheter Closure of Congenital Ventricular Septal Defects.经皮导管封堵先天性室间隔缺损
Korean Circ J. 2023 Mar;53(3):134-150. doi: 10.4070/kcj.2022.0336.
6
Transcatheter Closure of Perimembranous Ventricular Septal Defect Using the Lifetech Konar-Multi Functional Occluder: Early to Midterm Results of the Indonesian Multicenter Study.使用先健科纳多功能封堵器经导管闭合膜周部室间隔缺损:印度尼西亚多中心研究的早期至中期结果
Glob Heart. 2022 Feb 24;17(1):15. doi: 10.5334/gh.1106. eCollection 2022.
7
Transcatheter Closure of Perimembranous and Intracristal Ventricular Septal Defects Using Amplatzer Duct Occluder II in Children.经导管应用 Amplatzer Ⅱ型封堵器闭合膜周部和嵴内型室间隔缺损。
J Interv Cardiol. 2021 Sep 11;2021:4091888. doi: 10.1155/2021/4091888. eCollection 2021.
8
Transcatheter Device Closure of Perimembranous and Intracristal Ventricular Septal Defects in Children: Medium- and Long-Term Results.经导管膜周部和嵴内型室间隔缺损封堵术治疗儿童室间隔缺损:中远期结果。
J Am Heart Assoc. 2021 Jun;10(11):e020417. doi: 10.1161/JAHA.120.020417. Epub 2021 May 17.
9
A meta-analysis of perventricular device closure of doubly committed subarterial ventricular septal defects.双动脉下室间隔缺损经心室周围装置封堵术的荟萃分析。
J Cardiothorac Surg. 2020 Jan 28;15(1):28. doi: 10.1186/s13019-020-1062-0.
10
Transcatheter Closure of Perimembranous Ventricular Septal Defects in Children using a Wire-Drifting Technique.采用导丝漂移技术经导管封堵儿童膜周部室间隔缺损
Clinics (Sao Paulo). 2018 Nov 29;73:e371. doi: 10.6061/clinics/2018/e371.